Tolimidone

Tolimidone

Tolimidone is a pharmaceutical drug that was developed for the treatment of diabetes mellitus type 2. It belongs to the class of drugs known as hypoglycemic agents, which are used to lower blood glucose levels in patients with diabetes. Tolimidone works by stimulating the release of insulin from the pancreas, thereby reducing blood glucose levels.

History

Tolimidone was first synthesized in the 1970s by the pharmaceutical company Eli Lilly and Company. It was marketed under the brand name Orinase, but was later withdrawn from the market due to concerns about its safety profile.

Pharmacology

Tolimidone is a sulfonylurea, a class of drugs that stimulate the release of insulin from the pancreas. It works by binding to the sulfonylurea receptor on the pancreatic beta cells, which leads to an influx of calcium ions. This triggers the release of insulin, which in turn lowers blood glucose levels.

Side Effects

Like other sulfonylureas, Tolimidone can cause hypoglycemia (low blood sugar) if taken in excess or if the patient does not eat enough. Other side effects can include nausea, vomiting, diarrhea, and skin rash. In rare cases, Tolimidone can cause liver damage.

Withdrawal from Market

Tolimidone was withdrawn from the market due to concerns about its safety profile. Studies showed that it had a higher risk of causing liver damage compared to other sulfonylureas. As a result, it is no longer available for use.

See Also

• Sulfonylurea
• Diabetes mellitus type 2
• Insulin
• Hypoglycemia